Nuvation Bio (NUVB) Current Deferred Revenue (2024 - 2026)

Nuvation Bio (NUVB) has reported Current Deferred Revenue for 3 consecutive years, with $9.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 4771.5% year-over-year to $9.7 million; the TTM figure through Mar 2026 stood at $9.7 million (up 4771.5% YoY), while the FY2025 annual figure was $7.5 million, down 51.74% from the prior year.
• Current Deferred Revenue climbed to $9.7 million in Q1 2026 per NUVB's latest filing, from $7.5 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $15.6 million in Q4 2024 and bottomed at $200000.0 in Q1 2025.
• Historically, Current Deferred Revenue has averaged $9.2 million across 3 years, with a median of $10.4 million in 2025.
• Annual changes were most pronounced in 2025 — Current Deferred Revenue tumbled 63.11% — and 2026, when it surged 4771.5%.
• Nuvation Bio's Current Deferred Revenue stood at $15.6 million in 2024, then tumbled by 51.74% to $7.5 million in 2025, then climbed by 29.65% to $9.7 million in 2026.
• Business Quant data shows NUVB's Current Deferred Revenue at $9.7 million in Q1 2026, $7.5 million in Q4 2025, and $11.1 million in Q3 2025.